Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/10847| Title: | Burosumab in Unidentifiable Tumor-Induced Osteomalacia | Authors: | Der, Yi Shan Chaubey, Santosh McLean, Anna Trinh, Yasmin Pember, Shelley Sinha, Ashim |
Issue Date: | 2026 | Source: | Der YS, Chaubey S, Mclean A, Trinh Y, Pember S, Sinha A. Burosumab in Unidentifiable Tumor-Induced Osteomalacia. Clin Case Rep. 2026 Jan 19;14(1):e71600. doi: 10.1002/ccr3.71600. PMID: 41567527; PMCID: PMC12816759. | Journal Title: | Clinical case reports | Abstract: | Tumor-induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti-FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia. Our experience suggests that burosumab should be considered a first-line treatment. | Description: | Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated authors: Yi Shan Der, Santosh Chaubey, Anna McLean, Yasmin Trinh, Shelley Pember, Ashim Sinha | DOI: | 10.1002/ccr3.71600 | Keywords: | PTH/vit D/FGF23;bone scintigraphy;burosumab;osteomalacia and rickets;tumor‐induced bone disease | Type: | Journal article |
| Appears in Sites: | Cairns & Hinterland HHS Publications Queensland Health Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.